67 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
non-recoverable taxes or charges, including Value Added Tax.
“Expert” means a suitably qualified independent expert appointed by agreement between … are expressed to be exclusive of value added tax howsoever arising. If CRH is liable to pay value added tax in relation to any supply made or deemed to have
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee
8-K
EX-10.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
and are exclusive of any applicable value added tax or sales tax, which ValenzaBio shall be additionally liable to pay to ProBioGen if such tax is applicable.
9.2 … invoice.
10.2
Indirect Tax. All payments are exclusive of Indirect Tax. If any Indirect Taxes are chargeable in respect of any Payments, ValenzaBio
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
, liability, claim, expense, Tax, commitment or obligation of whatever kind, whether known or unknown, direct or indirect, accrued or fixed, absolute … Income to Seller under Section 3.4, as though Seller had entered directly into such sublicense with such Triggering Sublicensee.
“Tax(es)” means all
8-K
EX-99.5
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code
8-K
EX-99.4
15l5d 1mhbl1
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-99.6
t1zc99 458oqsq2lmzi
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-99.2
n5mgtnhmd eh
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
DEFA14A
22koa z8d0gl153fx
14 Jun 24
Additional proxy soliciting materials
5:02pm
8-K
EX-10.1
m5r7u
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
DEFM14A
cm0kg wr885d9c
4 Jun 24
Proxy related to merger
8:00am
PREM14A
ekj3rupu42voi
17 May 24
Preliminary proxy related to merger
4:36pm
10-K/A
h0txg pop74
29 Apr 24
Annual report (amended)
4:02pm
DEFA14A
luvgb
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-2.1
u697yo0gqwpf299e gd
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.1
da9re6
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.3
bksozsdo
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.2
1oxy24d24ifa 1rml78
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am